Previous Close | 10.74 |
Open | 10.58 |
Bid | 9.80 x 1000 |
Ask | 11.47 x 800 |
Day's Range | 10.50 - 10.78 |
52 Week Range | 7.61 - 19.99 |
Volume | |
Avg. Volume | 2,661,659 |
Market Cap | 1.967B |
Beta (5Y Monthly) | 2.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.09 |
Earnings Date | Feb 21, 2023 - Feb 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.30 |
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023. “We continue to build a consistent library of eviden
RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO® (berotralstat) in pediatric hereditary angioedema (HAE) patients who are 2 to <12 years of age. “Today’s announcement marks a very important step in our continuing efforts to reduce the burden of therapy for people living with HAE around the world with oral, once-daily OR
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO® (berotralstat) in Central and Eastern Europe (CEE). “We continue to build partnerships with companies that have deep expertise in commercializing rare disease therapies as we advance our mission of bringing ORLADEYO to patients living with hereditary angioedema around the world